AstraZeneca's Lumoxiti Receives FDA approval for the Treatment of R/R 2L+ Hairy Cell Leukemia in patients
Shots:
- The approval is based on P-III ‘1053’ trial conducted across 34 sites in 14 countries assessing Lumoxiti (moxetumomab pasudotox-tdfk) in patients with r/r HCL- testing its safety- efficacy- immunogenicity and PK
- P-III ‘1053’ trial (N=80) results: ORR (75%); DOR (30%); CR (41%); PRR (34%); hematologic remission rate (80%)
- Lumoxiti (CD22-directed cytotoxin) novel treatment in US for r/r HCL with recommended IV dose 0.04 mg/kg given over 30mins on days 1- 3 & 5 of each 28-day cycle up to 6 cycles- disease progression- or unacceptable toxicity
Ref: AstraZeneca | Image: AstraZeneca
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com